title: The anti-RAS cancer drug MKT-077 is an F-actin cross-linker.
authors.affiliation: Ludwig Institute for Cancer Research, Melbourne, Australia. hiroshi.maruta@ludwig.edu.au
authors.forename: H
authors.initials: H
authors.lastname: Maruta
authors.forename: A
authors.initials: A
authors.lastname: Tikoo
authors.forename: R
authors.initials: R
authors.lastname: Shakri
authors.forename: T
authors.initials: T
authors.lastname: Shishido
mesh_terms: D016475:3T3 Cells; D000199:Actins / Q000187:drug effects* / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002461:Cell Line, Transformed; D051379:Mice; D015689:Oncogene Protein p21(ras) / Q000037:antagonists & inhibitors*; D011725:Pyridines / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*
chemical_list: D000199:Actins; D000970:Antineoplastic Agents; D011725:Pyridines; D013844:Thiazoles; C097880:MKT 077; D015689:Oncogene Protein p21(ras)